Literature DB >> 12124228

A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning.

Dunli Wu1, Yi Soong, Guo-Min Zhao, Hazel H Szeto.   

Abstract

We recently discovered an opioid peptide analgesic, 2',6'-dimethyltyrosine (Dmt)-D-Arg-Phe-Lys-NH(2) ([Dmt(1)]DALDA), that can protect against ischemia-induced myocardial stunning. In buffer-perfused hearts, 30-min global ischemia followed by reperfusion resulted in a significant increase in norepinephrine (NE) overflow immediately upon reperfusion and significant decline in contractile force (45%). Pretreatment with [Dmt(1)]DALDA before ischemia completely abolished myocardial stunning and significantly reduced NE overflow (68%). In contrast, pretreatment with morphine before ischemia only provided brief protection against myocardial stunning and no reduction in NE overflow. [Dmt(1)]DALDA inhibited [(3)H]NE uptake into cardiac synaptosomes in vitro (IC(50) = 3.9 microM), whereas morphine had no effect. Surprisingly, protection against myocardial stunning was apparent even when hearts were perfused with [Dmt(1)]DALDA only upon reperfusion, whereas reperfusion with morphine had no effect. Binding studies with [(3)H][Dmt(1)]DALDA revealed no high-affinity specific binding in cardiac membranes, suggesting that the cardioprotective actions of [Dmt(1)]DALDA are not mediated via opioid receptors. These findings suggest that [Dmt(1)]DALDA is a potent analgesic that may be useful for myocardial stunning resulting from cardiac interventions or myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124228     DOI: 10.1152/ajpheart.00193.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  15 in total

Review 1.  Cell-permeable, mitochondrial-targeted, peptide antioxidants.

Authors:  Hazel H Szeto
Journal:  AAPS J       Date:  2006-04-21       Impact factor: 4.009

Review 2.  Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.

Authors:  Hazel H Szeto; Peter W Schiller
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

Review 3.  Mitochondria-targeted peptide antioxidants: novel neuroprotective agents.

Authors:  Hazel H Szeto
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 4.  Cardiac aging: from molecular mechanisms to significance in human health and disease.

Authors:  Dao-Fu Dai; Tony Chen; Simon C Johnson; Hazel Szeto; Peter S Rabinovitch
Journal:  Antioxid Redox Signal       Date:  2012-04-03       Impact factor: 8.401

5.  Targeting Myocardial Energetics in the Failing Heart: Are We There Yet?

Authors:  Douglas L Mann
Journal:  Circ Heart Fail       Date:  2017-12       Impact factor: 8.790

6.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.

Authors:  Eva Tomas; Joel F Habener
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

Review 7.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

8.  A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction.

Authors:  Yasunori Mizuguchi; Jie Chen; Surya V Seshan; Dix P Poppas; Hazel H Szeto; Diane Felsen
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-10

Review 9.  Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities.

Authors:  Ligia Akemi Kiyuna; Rudá Prestes E Albuquerque; Che-Hong Chen; Daria Mochly-Rosen; Julio Cesar Batista Ferreira
Journal:  Free Radic Biol Med       Date:  2018-09-15       Impact factor: 7.376

Review 10.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.